Leo-Pharma-blau.jpg
14/09/2018 16:13:38
Fuente original

New data show LEO Pharma’s Kyntheum® (brodalumab) provides greater probability of achieving complete skin clearance for people with moderate to severe psoriasis compared with ustekinumab

Possibility of complete clearance of psoriasis symptoms can have a transformational impact on happiness, according to a new European survey of more than 7,000 people living with the disease.

Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, show that treatment with LEO Pharma’s Kyntheum® (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab.1,2  The possibility of attaining completely clear skin makes a significant difference to the lives of people with psoriasis, according to the newly published PsoClear Report.3 

Outcomes of the first of two analyses of pooled data from the AMAGINE-2 and AMAGINE-3 studies showed a greater proportion of those taking Kyntheum® achieved (absolute) PASI 0, meaning complete skin clearance without any symptoms of psoriasis, over time compared with ustekinumab (75% versus 52%, respectively at 52 weeks).1 Absolute PASI scores measure the severity of redness, thickness and scaling of skin on different parts of the body, whereby a score of less than three is indicative of treatment success. 4 Results of the second analysis found that the time it took for 50% of patients to achieve complete clearance across all body regions – head and neck, trunk, upper limbs and lower limbs – was shorter with Kyntheum® than ustekinumab. Over the course of the 52-week analysis, superior rates of complete clearance were seen as early as week two for Kyntheum® treated patients.2 

Professor Marc Radtke, Institute for Health Care Research in Dermatology and Nursing, Hamburg, Germany, commented, “Even when a relatively small proportion of body surface is affected by psoriasis, it can still impose a substantial burden. The latest Kyntheum® data are of interest to clinicians and patients, because they show what the treatment can achieve overall and on specific body regions. This gives reassurance that high levels of skin clearance are increasingly possible with newer treatments.”

Achieving complete skin clearance is a significant milestone for people with psoriasis and one which has a direct correlation to their quality of life, including their happiness levels.3,5,6  The recent PsoClear Report of 7,644 Europeans, showed those living with disease would be, on average, 49% happier if they achieved clear skin, defined as skin that is completely free of lesions and symptoms like itchiness and scaling.3 Nearly one in four (24%) felt achieving skin clearance would allow them to live their best possible life, giving their potential happiness level a top ranking on a 10 point happiness scale.3 However, not all of those surveyed felt so optimistic. Nearly two-thirds (63%) of people living with psoriasis believe achieving clear skin is impossible or very unlikely.3 

“With treatments, like Kyntheum®, that can offer more people a chance for complete skin clearance, it’s time to better understand and appreciate the importance and impact this improvement can have on a person’s life,” said Gitte Aabo, President & CEO, LEO Pharma. “At LEO Pharma, helping people achieve healthy skin is at the heart of all we do and we want all people with psoriasis to have the chance to experience the transformative difference complete clearance makes.” 

A total of 13 abstracts on brodalumab and complete skin clearance in psoriasis are being presented at the 2018 EADV annual congress.



Leer el artículo original completo

Otras noticias que pueden interesarle